GO
Loading...

Enter multiple symbols separated by commas

Search results for "ARIA"

REFINE RESULTS

SEARCH RESULTS

About 6 results. Sort By: Date | Relevance
These biotech names are ripe for mergers: Analysts

Synageva isn't the only eligible takeout target in biotech. Meg explains who industry analysts are pointing to as the next takeout candidates.
Source: CNBC.com | By: Leanne Miller
Biotech takeover targets  

CNBC's Meg Tirrell discusses possible merger and acquisitions in the biotech space.
Source: CNBC.com
Sarissa Capital's biotech bets  

Alex Denner, Sarissa Capital Management founder, discusses the opportunity in ARIAD Pharmaceuticals.
Source: CNBC.com
UPDATE 1-Ariad Pharma CEO Berger to retire in deal with top investor

April 29- Ariad Pharmaceuticals Inc said Chief Executive Harvey Berger would retire as part of a deal to settle its proxy battle with largest shareholder Sarissa Capital Management. Ariad's shares were up 4 percent at $9.22 in premarket trading. Sarissa, an activist fund run by investor Carl Icahn's former healthcare lieutenant, Alex Denner, holds a 6.85...
Source: Reuters
Ariad CEO to retire in deal with activist Sarissa

Ariad Pharmaceuticals CEO Harvey Berger will retire this year in a settlement with hedge fund Sarissa Capital, capping months of agitation.
Source: CNBC.com | By: Meg Tirrell
Ariad CEO Berger to step down in settlement deal with Sarissa

April 29- Sarissa Capital Management LP said Ariad Pharmaceuticals Inc's Harvey Berger would retire as CEO as part of a deal to settle the hedge funds's proxy battle with the drugmaker.
Source: Reuters